Monitoring the intrahepatic innate immune responses in chronic HBV patients treated with tenofovir

Monitoring the intrahepatic innate immune responses in chronic HBV patients treated with tenofovir - IntraHepB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33915

Enrollment

Registered

2008-11-19

Start date

2009-02-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV hepatitis B

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Male and female older than 18 years, with evidence of a chronic HBV infection - Indication for antiviral therapy of chronic HBV accorind to current clinical guidelines - Written informed consent

Exclusion criteria

Exclusion criteria: - Other causes of liver disease/co-infections - Other significant comorbidities - Presence of contra-indications for antiviral therapy with tenofovir

Design outcomes

Primary

Measure	Time frame
Outcome measurements Peripheral blood -Frequency, phenotype and function of NK cells,Treg and DCs. -Determination of HBV-specific T cell response -Determination of HBV and proteins in/on NK cells Intrahepatic -Frequency, phenotype and function of intrahepatic NK cells and DCs	—

Secondary

Measure	Time frame
No extra secundary outcome variables	—

Countries

Netherlands

Outcome results